Rationale: Fibrosis after lung injury is related
Methods: We used tissue sections, plasma, and lung fibroblasts from patients with IPF and control subjects. In a bleomycin-induced lung fibrosis model we used wild-type MMTV mice and a triple transgenic mouse SPC-rtTA Conclusions: These results indicate that changes in the bioavailability of VEGF-A sourced from ATII cells, namely the ratio of VEGF-A xxx a to VEGF-A xxx b, are critical in development of pulmonary fibrosis and may be a paradigm for the regulation of tissue repair.
Keywords: idiopathic pulmonary fibrosis; vascular endothelial growth factor; animal models of pulmonary fibrosis Fibrosis in the lung or elsewhere is part of the normal repair mechanism after injury. Idiopathic pulmonary fibrosis (IPF) can be considered as a paradigm of an aberrant repair process in response to repeated and unidentified injury. IPF is a devastating progressive fibrosing lung disease of unknown cause that is increasing in incidence (1) . Median survival is 3-5 years and treatment options are limited (2, 3) , leading to an estimated mortality rate of more than 50 deaths per 1,000,000 persons in the United States (4) and United Kingdom (1) .
Vascular endothelial growth factor (VEFG)-A, originally described as an angiogenic factor, belongs to a super-family of glycoproteins, and signals through tyrosine kinase receptors VEGF receptor 1 (VEGFR1) and VEGF receptor 2 (VEGFR2) and coreceptors, neuropilin (NP) 1 and 2 (5, 6) . However, VEGF biology has undergone radical revision since its discovery. It has been identified in primitive organisms that have no vasculature (7) , is not specific to endothelial cells, and is increasingly recognized as vital in the function and maintenance of nonendothelial cells (8, 9) . In vitro studies have confirmed that VEGF-A is abundant in lung tissue, especially in alveolar epithelium (10) (11) (12) (13) (14) , and has a role in lung development (15) and maturation (16) . In the healthy lung processes classically associated with VEGF-A are extremely restricted (14, 17, 18) . This apparent paradox has led to controversy about the role of VEGF-A in the normal and diseased lung (19) .
Several pathogenic mechanisms for the development of IPF have been proposed but currently a form of recurrent alveolar type II (ATII) epithelial injury leading to aberrant collagen deposition from fibroblasts is most widely accepted (20) . Evidence on the role of VEGF-A in IPF conflicts (21) (22) (23) . Evidence that VEGF-A may facilitate fibrogenesis comes from the extensive trials of Food and Drug Administration-approved nintedanib, a triple tyrosine kinase inhibitor, including the VEGFR2 receptor (24, 25) . In contrast, several clinical studies have indicated a reparative role for VEGF-A in the lung (17, 18) , with preclinical studies suggesting a protective role for VEGF-A against the development of excessive pulmonary fibrosis as a result of lung injury (26) (27) (28) .
Differential splicing of the VEGF-A gene produces multiple functional isoforms (29) : proximal splice site selection with exon 8 produces the conventional family of VEGF-A xxx a isoforms. Distal splice site selection within exon 8 produces an alternative family of isoforms (VEGF-A xxx b family), which have the same number of amino acids as the conventional family in humans, but six different amino acids at the C terminus (30) . The most widely studied of these isoforms, VEGF-A 165 b, is functionally different from VEGF-A 165 a (30, 31) . VEGF-A 165 b inhibits canonical VEGF-A signaling by competitive interference with conventional isoforms at the VEGFR2-NP1 receptor complex, preventing full downstream signaling by VEGFR2 (32) . Knowledge of inhibitory VEGF-A variants in clinical tissue repair syndromes is limited (33) . We have shown that they inhibit VEGF-A 165 a-induced ATII and pulmonary microvascular proliferation in vitro (10) . Functional murine VEGF-A 165 b has been described (33) . Thus a number of regulatory events at the 39 end of the VEGF-A gene are required for precise physiologic control of VEGF-A bioavailability (34) .
Until now, studies have examined VEGF as a single molecule. Differential expression of the numerous VEGF-A isoforms offers one explanation for the apparent discrepancies observed in the literature. In this study we have focused on the role of VEGF-A in relation to fibroblast function. We show that ATII cell-specific production of VEGF-A is a key checkpoint for controlling lung fibrogenesis. VEGF-A 165 b acts as a natural regulator of this process and has potential therapeutic applications for restoring homeostasis to the lung and treating fibrosis. Some of the results have been previously reported in abstract form (35) (36) (37) .
Methods

Human Tissue Collection
Anonymized human lung biopsies and bronchoalveolar lavage (BAL) were donated from patients undergoing clinically indicated procedures. The Bristol institutional review boards granted ethical approval. Additional IPF tissue and plasma samples came from the Lung Tissue Research Consortium and Toby Maher (Royal Brompton Hospital, London UK) (38) .
Primary Lung Fibroblast Culture
Primary lung fibroblasts were explanted from lung biopsies as previously described or obtained from the American Type Culture Collection.
Reverse Transcription-Polymerase Chain Reaction and Quantitative Reverse Transcription-Polymerase Chain Reaction
Total RNA was extracted using the Quick RNA kit (Zymo Research Irvine, CA) and reverse transcribed with Taqman High Capacity RNA-to-cDNA kit (Applied Biosystems, Foster City, CA). Individual quantitative reverse transcriptionpolymerase chain reaction (qRT-PCR) reaction mixes were made using manufacturer recommendations (23 SensiFAST SYBR Hi-ROX; Bioline, London, UK). Human and murine primer sets are in Tables E1 and E2 in the online supplement. Expression of human VEGF-A xxx a and VEGF-A xxx b isoforms were also quantified (39) .
Cell Immunofluorescence
Cells were fixed, permeabilized, and blocked before incubation with primary antibody overnight and then secondary antibody before image capture.
Western Blot Analysis
Cell lysates were prepared using radioimmunoprecipitation buffer (Sigma, St. Louis, MO), containing protease and phosphatase inhibitor cocktails (Sigma). Lysates were fractionated, immunoblotted, blocked, then incubated with primary antibodies and loading controls. ) were generated as previously described (41) . SPC-rtTA
At a Glance Commentary
LoxP VEGF 1/1 mice were generated on C57Bl6 background by crossing three transgenic mouse lines: LoxP-VEGF (Genentech, San Francisco, CA) (42), Cre-recombinase, under control of a tetracycline-responsive promoter element (Tet-O) and TG mice expressing the reverse tetracycline-controlled transactivator (rtTA) protein under control of surfactant, pulmonary-associated protein C, promoter (SPC) (Jackson) (43) .
Animal Studies
The bleomycin (BLM)-induced model of pulmonary fibrosis was used (44) . Lung fibrosis was assessed by fibronectin and procollagen-1a mRNA expression and histologically by Masson trichrome staining and lung fibrosis score. Further experimental details are available in the online supplement.
Statistical Analysis
Statistical analysis was performed using GraphPad Prism software version 5.0 (GraphPad Software Inc., San Diego, CA). Unpaired Student's t test was used, with or without Welch correction dependent on the variance of data. Analysis of variance with post hoc Holm-Šidák multiple comparisons analysis was used for multiple comparisons. For all tests a P less than 0.05 was considered statistically significant. Figure 1A ), confirmed by sequencing (see Figure E1 ) and quantified ( Figure 1B ). Pan-VEGF-A protein levels in whole lung were comparable between normal and IPF, but intriguingly VEGF-A 165 b protein expression was dramatically increased in IPF lung tissue ( Figure 1C ). VEGF-A 165 b, but not pan-VEGF-A, in baseline plasma samples of subsequent progressors (death or .10% decline in FVC at 12 mo) were significantly greater than nonprogressors ( Figure 1D ).
Levels of VEGF-A (representing only the soluble isoforms, VEGF-A 121 and VEGF-A 165 ), investigated by pan-VEGF-A ELISA, were significantly lower in BAL fluid (BALF) of patients with IPF compared with control subjects (Figure 1E ), as previously reported (13, (45) (46) (47) . Patient demographics were comparable (see Figure  E2A ). VEGF-A 165 b was undetectable in BALF, using an ELISA specific for an epitope encoded by exon 8b suggesting it was not secreted into an area accessible by this procedure or was below the detection limit (10 pg/ml). Using immunohistochemistry, we found that in both normal and IPF lung pan-VEGF-A and VEGF-A 165 b were prominent within alveolar epithelium ( Figure 1F ; see Figure E2B ) but also localized to macrophages, lymphocytes, and fibroblasts, particularly outside the fibrotic focus. These data suggest that there is an increased expression of VEGF-A 165 b in IPF, one source being ATII cells as previously shown in normal lung (10) . To understand the biologic potential of these findings in IPF we investigated the expression of the receptors and coreceptors necessary for functional activity.
VEGF Receptor and Coreceptors in Patients with IPF
Expression of VEGFR1, VEGFR2, NP1 and NP2 was detected at the mRNA level in normal and IPF lung whole-lung tissue ( Figure 2A ). Expression of VEGFR1 and NP1 was significantly up-regulated in IPF lung. (38) . There was a significant difference in plasma levels of VEGF-A 165 b in progressors (n = 10) compared with nonprogressors (n = 15) (*P , 0.05; unpaired Student's t test). (E) Pan-VEGF-A levels in bronchoalveolar lavage fluid (BALF) of patients with IPF (n = 15) compared with control subjects (n = 13) using an antibody that does not discriminate between isoforms. Patient demographics were statistically comparable by unpaired Student's t test (see Figure E2A ). Pan-VEGF-A BALF levels were significantly lower in the IPF group compared with control subjects, **P , 0.01, unpaired Student's t test with Welch correction. Data are presented as means with SEM. Mean pan-VEGF-A expression in control group 85.7 pg/ml 6 17.1, versus IPF 18.0 pg/ml 6 6.1. VEGF-A 165 b expression was below the limit of detection in both patients with IPF and control subjects (10 pg/ml). (F) Pan-VEGF-A and VEGF-A 165 b immunohistochemical staining. Intense staining of the alveolar epithelium was observed for both pan-VEGF-A and VEGF-A 165 b in normal and IPF lungs (least and most fibrotic designated as in Ashcroft and colleagues [59] and Ebina and colleagues [60] ) (arrows). Additional sites of localization included vessel walls (arrowheads), fibroblasts, lymphocytes, and alveolar macrophages. Isotype IgG shown as negative control. Scale bars = 10 mm; original magnification, 3100. Lowermagnification images are shown in Figure E2B . AM = alveolar macrophages; FFo = fibrotic focus. (A) Quantitative reverse transcription-polymerase chain reaction of VEGFR1, VEGFR2, neuropilin (NP) 1, and NP2 mRNA expression in whole-lung RNA extracts of normal (n = 5) and IPF (n = 5) lung. VEGFR1 (*P , 0.05; unpaired Student's t test) and NP1 (*P , 0.05; unpaired Student's t test) mRNA expression was significantly up-regulated in the IPF lung. Data are presented as mean fold change in expression (2 2DDCT ) with SEM, data analysis performed on DDCT values. (B) VEGF-A receptor and coreceptor immunohistochemical staining. Intense staining of the alveolar epithelium was observed for VEGFR1, VEGFR2, NP1, and NP2 (arrows) in both the normal and IPF lung. Additional sites of localization included the vascular endothelium (arrowheads), fibroblasts, lymphocytes, and alveolar macrophages. Isotype IgG shown as negative control subject. Images were taken at 340 magnification; scale bars = 25 mm. Additional higher-magnification images are shown in Figure E3B . (C) Expression of VEGFR1, VEGFR2, NP1, and NP2 in whole-tissue lysates of normal (n = 5) and IPF (n = 5) lung by Western blotting (top) with semiquantitative densitometric analysis (bottom). VEGFR1, VEGFR2, NP1, and NP2 were expressed in both the normal and IPF lung. VEGFR1 (*P , 0.05) was significantly down-regulated in the IPF lung (unpaired Student's t test, data presented as mean densitometry score with SEM). AM = alveolar macrophages; F = IPF lung; FFo = fibrotic focus; N = normal lung. Using immunohistochemistry, we found that in normal and IPF lung VEGFR1, VEGFR2, NP1, and NP2 were expressed on alveolar epithelium, macrophages, lymphocytes, and fibroblasts surrounding fibrotic foci with reduced expression within the foci ( Figure 2B ; see Figure E3A ).
Lung whole-tissue lysates expressed VEGFR1, VEGFR2, NP1, and NP2 protein ( Figure 2C ). There was a significant reduction in protein expression of VEGFR1 in the whole IPF lung samples with a trend to reduced VEGFR2 and NP1. Costaining of VEGFR1 and VEGFR2 with epithelialspecific E-cadherin suggests that nonendothelial cells are VEGF-A targets (see Figure E3B ).
These data demonstrated the potential for VEGF-A to have functional effects in fibrotic lung. In this context, we then looked at isolated fibroblast cultures, the potential effector cells, from IPF and normal subjects.
VEGF-A Receptors and Coreceptors Are Expressed by Primary Lung Fibroblasts, and VEGF-A Stimulation Stimulates Downstream Signaling Pathways
VEGFR1, VEGFR2, NP1, and NP2 were endogenously expressed by fibroblasts from normal subjects (NF) and patients with IPF (FF), at the mRNA level (see Figure E3C ). FF expressed less VEGFR1 and NP2 protein ( Figure 3A) . Surprisingly, these cells did not express mature VEGFR2 protein by Western blotting. These results were corroborated by ELISA; the expression of VEGFR2 was below the detection limit (<30 pg/ml). VEGFR2 is conventionally considered the main signaling receptor so we investigated whether signaling could occur. Treatment of NF and FF cultures with rhVEGF-A 165 a or rhVEGF-A 165 b proteins led to increased phosphorylation of MEK1/2 (Mitogen/Extracellular signal related Kinase) and p42/44 MAPK (Mitogen Activated Protein Kinase) proteins ( Figure 3B ; see Figure E4 ).
VEGF-A Isoforms Are Expressed in Primary Lung Fibroblasts
NF and FF were characterized as expressing three major VEGF-A isoforms detectable at the RNA level by RT-PCR and confirmed by sequencing (see Figures  E5 and E6 ). Comparable levels of pan-VEGF-A and VEGF-A xxx b mRNA were demonstrated in NF and FF by qRT-PCR (see Figure E7 ).
In contrast, comparable protein expression of pan-VEGF-A, but increased expression of VEGF-A xxx b isoforms in FF cell lysates, was identified by Western blotting ( Figure 3C ). Quantification of pan-VEGF-A and VEGF-A xxx b protein expression in cell lysates of NF and FF cultures by ELISA supported these findings ( Figure 3D ).
Localization of pan-VEGF-A and VEGF-A 165 b expression by immunofluorescence demonstrated cytoplasmic localization in all NF and FF, with additional pan-VEGF-A perinuclear staining ( Figure 3E ; see Figure E8 ). These data suggest an additional potential for autocrine effects of pan-VEGF-A and VEGF-A 165 b on fibroblasts.
Having shown the potential for functional effects of VEGF-A 165 a and VEGF-A 165 b on fibroblasts we then explored how they might relate to IPF pathology. (Figures 4A-4C) . Figures 4A and 4C ). However, with increasing levels of VEGF-A 165 b, the VEGF-A 165 a-induced increase in fibronectin was inhibited, an effect more apparent for FF ( Figure 4B ). In the presence of both isoforms, VEGF-A 165 b inhibited collagen production in NF but not FF ( Figure 4C Figure 4E ; see Figure E9 ).
VEGF-A 165 a and VEGF-
Collectively these data supported an in vitro mechanism by which VEGF-A 165 a could induce a fibrotic response Figure E8 . FF = patients with idiopathic pulmonary fibrosis; NF = normal subjects; Tub = tubulin. To determine the effect of VEGF-A on the development of BLM-induced pulmonary fibrosis (44), we generated a triple transgenic mouse SPC-rtTA
LoxP-VEGF-A 1/1 (termed STCLL) on a C57Bl/6 background to conditionally induce the deletion of VEGF-A isoforms specifically in the ATII cells of adult mice. Tissue specificity of Cre-recombinase activity after doxycycline induction was confirmed by in vivo imaging of doxycycline-induced GFP-SPCrtTA
mice (termed GFP-STCL) ( Figure 5A ; see Figure E10 ). Quantitative RT-PCR of whole-lung tissue RNA extracts demonstrated reduced pan-VEGF-A in doxycycline-induced TG mice. In situ hybridization indicated a lack of VEGF-A mRNA in the murine ATII cells and pan-VEGF-A immunohistochemistry corroborated findings of reduced ATIIderived VEGF-A ( Figure 5A ). Deletion of ATII VEGF-A significantly reduced the development of BLM-induced pulmonary fibrosis by both a blindly assessed lung fibrosis score and reduced collagen deposition and architectural distortion ( Figure 5B ). Furthermore, lung fibronectin mRNA expression was significantly reduced in BLM-treated STCLL mice compared with BLM-treated wild-type (WT) control animals, with a trend toward a reduction in pro-collagen1a mRNA levels in these TG mice ( Figure 5B ). This demonstrates that ATII expression of VEGF-A is required for fibrosis to occur.
VEGF-A 165 b May Be Protective against the Formation of Pulmonary Fibrosis
A TG mouse that overexpresses VEGF-A 165 b using a MMTV promoter as a driver of expression has been described (41) . This mouse has increased levels of the MMTV-VEGF-A 165 b transgene and human VEGF-A 165 b in the lung (see Figure E11A ). Hematoxylin-eosin-stained lung sections of TG mice were histologically normal, in particular with no vascular abnormalities, as might be expected in view of the established compartmentalization of lung VEGF (see Figure E11B ) (14) . Immunohistochemical staining of TG mouse lung sections demonstrated increased VEGF-A 165 b expression localized to alveolar epithelial cells, compared with both mouse IgG and WT control animals ( Figure 6A ). Homogenized lung tissue extracts from MMTV-VEGF-A 165 b mice expressed significantly more VEGF-A 165 b protein than littermate WT control animals by ELISA, with detectable VEGF-A 165 b levels in BALF of TG mice, but below the detection limit of the ELISA in WT control animals ( Figure 6A) . In this preclinical model the development of pulmonary fibrosis was significantly reduced in TG mice compared with WT mice ( Figure 6B ). Pro-collagen-1a mRNA levels were significantly reduced in BLM-treated TG mice compared with BLM-treated WT littermates, with a trend to reduction in fibronectin mRNA in these same TG mice ( Figure 6B ). These data show a protective effect of VEGF-A 165 b within the lung when expressed particularly by the alveolar epithelium, supporting a potential for therapeutic application.
To determine the effect of VEGF-A 165 b on the development of BLM-induced pulmonary fibrosis, WT C57/Bl/6 mice received oropharyngeal BLM with or without the additional intraperitoneal (IP) delivery of rhVEGF-A 165 b. Importantly, in one arm of the study, to specifically address the potential therapeutic benefit of VEGF-A 165 b, the compound was delivered during the fibrotic rather than the inflammatory phase of the model (late VEGF-A 165 b group).
IP injection of VEGF-A 165 b significantly reduced the development of pulmonary fibrosis in WT mice. This protective effect of VEGF-A 165 b was evident in the early VEGF-A 165 b and late VEGF-A 165 b groups suggesting a protective effect of VEGF-A 165 b ( Figure 6C ). Although the expression of fibronectin and pro-collagen-1a mRNA in whole-lung tissue RNA extracts was significantly up-regulated in mice treated with BLM plus saline IP, the expression in both VEGF-A 165 b IP groups was not significantly different from oropharyngeal saline-treated control subjects, supporting the notion that VEGF-A xxx a is profibrotic and VEGF-A xxx b is protective.
Discussion
Although VEGF-A has been implicated in the response of the lung to injury there are LoxP 1/2 transgenic (TG) mice (STCL) to determine the period of doxycycline induction required to activate the Cre-recombinase and to identify the tissue specificity of Cre-recombinase activity after doxycycline induction. The reporter mice possess LoxP sites on either side of a membrane-targeted tdTomato (mT) cassette and express red fluorescence in all tissues. In the presence of Cre recombinase, the mT cassette is deleted, allowing expression of the membrane-targeted EGFP (mG) cassette located just downstream.
conflicting reports as to whether it functions as a contributory or protective factor (21, 22, 27, 28) . Processes classically associated with VEGF-A are extremely restricted within the normal lung (14, 17, 18) , which reflects the increasing recognition of VEGF as vital in the function and maintenance of nonendothelial cells (8, 9 . Cumulative evidence from several studies has suggested that the alternatively spliced VEGF-A xxx b isoforms may have opposing/inhibitory functions compared with the conventional VEGF-A xxx a family (31) and appreciation of the existence of numerous VEGF-A isoforms and their interaction with VEGF-A receptors and cofactors determining VEGF-A bioavailability, offers one potential explanation for these discrepant findings.
We show that differential expression of VEGF-A xxx a and VEGF-A xxx b isoforms in the IPF lung can result in functional changes to the fibrotic process, and that ATII cell VEGF-A is critical for the development of fibrosis in a preclinical murine model. The finding that in this model fibrosis can be prevented or resolved by expression of the inhibitory isoform indicates that it is the VEGF-A xxx a family that is profibrotic and the VEGF-A xxx b family is inhibitory/regulatory. This leads to two potential new therapeutic approaches for IPF: selective inhibition of VEGF-A xxx a, or stimulation (or administration) of VEGF-A 165 b. The development of a specific VEGF-A 165 a antibody (48, 49) and small molecule splicing agents that alter the relative balance of VEGF-A isoforms (50, 51) could facilitate this.
We have shown significant upregulation of VEGF-A 165 b within IPF lung tissue compared with normal lung. This was particularly seen in both ATII cells and fibroblasts (outside the fibrotic foci) in the most severely fibrotic areas of the IPF. These data were obtained from patients with established disease suggesting that dysregulated fibrosis has occurred despite these changes. We speculate that the increase in VEGF-A 165 b is a compensatory mechanism that was insufficient to prevent inappropriate fibrosis in these patients; however, in some patients at risk, fibrosis will be prevented. Sequential lung tissue data to support this is not available because these patients present with established disease. However, increased VEGF-A 165 b in baseline plasma samples from patients with subsequent progression supports this hypothesis (38) . In contrast, we found a significant reduction in pan-VEGF-A expression in the BALF of patients with IPF by ELISA as previously observed (45) (46) (47) and VEGF-A 165 b levels were undetectable in identical BALF samples. The nature of BALF collection from IPF lung would favor least affected areas and the greatest intensity of immunohistochemical staining for VEGF-A 165 b was in the most fibrotic areas.
The isoform production switch, altering the ratio of VEGF-A xxx a to VEGF-A xxx b, could be viewed as a contributor to disease, or as a protective response of the ATII and other cells, a regulatory mechanism to maintain homeostasis as we have previously postulated in the lung (10) and others in systemic sclerosis (52, 53) . Interestingly, it has become clear that IPF is associated with multiple splicing changes, such as that required for VEGF-A 165 b (54, 55) .
VEGFR1 was down-regulated in IPF and expression was low in fibrotic fibroblasts, with additional trends toward a reduction in both VEGFR2 and NP1 expression in IPF. This may be caused by the presence of increased VEGF-A 165 b that has been shown to cause down-regulation of VEGFR2, because it results in internalization and degradation through the endosomal pathway (32) . Although fibroblasts lack VEGFR2, historically considered the most biologically active of all the VEGF receptors (56), we demonstrated that recombinant VEGF-A proteins have differential effects on the proliferation, migration, and ECM protein expression by these cells. Given that VEGF-A 165 b levels are raised in IPF, and VEGF-A 165 a stimulates profibrotic effects in fibrotic fibroblasts, which were inhibited by VEGF-A 165 b, this could be a protective mechanism in IPF that is being overwhelmed by the other inflammatory processes being driven forward (57) . VEGF-A has been shown to have both paracrine and autocrine effects on several cell types within the lung (6, 10, 15, 16) . It is our opinion that although the statistically significant differences observed in fibroblast responses to VEGF-A isoforms might seem biologically modest, they could have important implications in a slowly progressive fibrosing disease, such as Images were taken at 340 magnification; scale bar = 25 mm, n = 3. GFP fluorescence was absent in the kidneys and liver (see Figure E10) . Using a murine VEGF-A RNA probe, in situ hybridization demonstrated a reduction in ATII cell staining (reduction in blue/black signal) in induced-TG mice compared with induced-WT mice (arrows). Pink staining represents nuclear fast red counterstain (n = 3; images taken at 3100 magnification; scale bar = 10 mm). Pan-VEGF-A mRNA expression was significantly reduced in whole-tissue RNA extracts from TG mice compared with WT mice (n = 6; **P , 0.01; unpaired Student's t test; data presented as means with SEM). Consistent with these findings, immunohistochemical staining for pan-VEGF-A also showed a reduction in ATII cell staining in induced-TG mice compared with induced-WT mice (n = 3; images taken at 3100 magnification; scale bar = 10 mm). (B) Postnatal deletion of VEGF-A from ATII cells ameliorates the development of bleomycin (BLM)-induced pulmonary fibrosis. Masson trichrome staining of mouse lung sections, with lung fibrosis score (above) and quantitative reverse transcription-polymerase chain reaction of FN and procollagen1a mRNA levels (below). As demonstrated by Masson trichrome staining, administration of BLM to both WT (g-i) and noninduced STCLL (j-l) mice resulted in extensive pulmonary fibrosis. This effect was ameliorated in BLM-treated doxycycline-induced STCLL mice (m-o). Images were originally 310 magnification; scale bar = 100 mm; n = 5 or 6; n = 3 shown. The lung fibrosis score of BLM-treated, doxycycline-induced STCLL mice was significantly reduced compared with BLM-treated control animals (induced-WT mice **P , 0.01 and noninduced STCLL mice **P , 0.01; n = 5). The expression of FN and pro-collagen-1a mRNA was significantly up-regulated in the lungs of BLM-treated, doxycycline-induced WT mice compared with saline-treated control animals (****P , 0.001; n = 5 or 6 analyzed). FN and pro-collagen-1a expression was significantly up-regulated in BLM-treated, doxycycline-induced TG mice compared with TG saline controls (*P , 0.05; **P , 0.01; n = 5). Furthermore, FN mRNA levels were significantly reduced in BLM-treated TG mice compared with BLMtreated WT mice (*P , 0.05; n = 5), with a trend toward a reduction in pro-collagen-1a levels in these same mice (P = 0.08, n = 5). Statistical analysis: analysis of variance with Holm-Šidák multiple comparisons test used throughout. n/s = not significant; STCLL = SPC-rtTA -i) . The development of BLM-induced pulmonary fibrosis was ameliorated in TG mice. Saline control subjects are shown in a-f (n = 6 per group; n = 3 shown). Scale bar = 100 mm; original magnification, 310. The lung fibrosis score of BLM-treated WT mice was significantly greater than saline-treated WT mice (****P , 0.0001; n = 6 per group). The lung fibrosis score of BLM-treated TG mice was significantly lower than BLM-treated WT mice (***P , 0.001; n = 6 per group). FN mRNA was significantly up-regulated in the lungs of WT BLM-treated mice compared with WT saline-treated control animals (**P , 0.01; n = 6 analyzed) and in TG BLM-treated mice compared with TG saline-treated control animals (*P , 0.05; n = 6). There was no statistical difference between BLMtreated WT and TG mice (P = 0.09; n = 6). In contrast, pro-collagen-1a mRNA levels were significantly reduced in BLM-treated TG mice compared with BLM-treated WT littermates (*P , 0.05; n = 6). IPF, in which tissue remodeling and disease progression is best observed over months and years. Although in vitro studies using cocultures of IPF-derived alveolar epithelium and fibroblasts would be desirable to further study this mechanism, there are several recognized practical limitations to culturing IPF epithelial cells (58) .
In our initial studies of a preclinical pulmonary fibrosis model, we sought to determine the critical source of VEGF-A. We demonstrated a significant amelioration of the fibrotic response in a specific doxycycline-induced ATII cell VEGF-A-deficient mouse showing that alveolar production of VEGF-A is required for fibrosis to occur. VEGF-A was not completely absent in this model, which is likely to reflect the situation in the human lung. We did not find any evidence of vascular abnormalities in our model, although functional vascular studies were not undertaken. This supports the widely accepted notion in the pathogenesis of IPF that is of initiation by recurrent epithelial injury (20) .
Using this same preclinical model, we explored the potential therapeutic benefit of IP rhVEGF-A 165 b administration. The BLM-model of lung fibrosis has been characterized as having an early partially inflammatory phase followed by a fibrotic phase (44) . In our study, both early IP VEGF-A 165 b and critically late IP VEGF-A 165 b, delivered specifically in the "fibrotic phase" of the fibrosis model, resulted in significant amelioration of pulmonary fibrosis. In conjunction with the previous data this demonstrates that it is VEGF-A xxx a isoforms that are required for fibrosis.
These data support our hypothesis that the coordinated expression of VEGF-A xxx a and VEGF-A xxx b isoforms is important in the development and progression of pulmonary fibrosis. Differential expression of these families of VEGF-A isoforms may explain, in part, some apparently contradictory studies describing VEGF-A as both a protective and contributory factor in fibrogenesis. We describe for the first time the apparent protective effects of VEGF-A xxx b expression in preclinical models of pulmonary fibrosis, an effect that may occur because of differential effects on fibroblastic synthetic function. Our findings support a "nonangiogenic/ nonvascular" role for VEGF-A in the fibrotic lung. Future studies are required to elucidate further mechanisms by which VEGF-A xxx b may inhibit fibrogenesis and to address factors that may regulate alternative splicing of the VEGF-A gene. n 
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